Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

NCT05626634 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Developmental and Epileptic Encephalopathy
Dravet Syndrome
Lennox-Gastaut Syndrome

Interventions

DRUG: LP352, bexicaserin

Sponsor

Longboard Pharmaceuticals